Chromatide Closes VC Round with Existing Investors | GenomeWeb

NEW YORK (GenomeWeb News) — UK-based synthetic polymer company Chromatide said today that it has received an undisclosed second round of financing from Enterprise Ventures and Alliance Fund Managers, both of which invested in it in 2007.

Chromatide, which plans to use the money to continue expanding its IP portfolio, said that since the first investment it has "successfully delivered on a range of technical and commercial" milestones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.